Mizuho Maintains Buy on CRISPR Therapeutics, Raises Price Target to $99
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has maintained a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $82 to $99.
March 06, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Salim Syed reaffirmed a Buy rating on CRISPR Therapeutics and raised the price target from $82 to $99.
The increase in price target by a reputable analyst like Salim Syed suggests a strong confidence in CRISPR Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term increase in CRSP's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100